Holen Sie sich die Stockscreener-App
12.14
0.57%
-0.07
Schlusskurs vom Vortag:
$12.21
Offen:
$12.07
24-Stunden-Volumen:
16,533
Relative Volume:
0.34
Marktkapitalisierung:
$60.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.49M
KGV:
-4.0947
EPS:
-2.9648
Netto-Cashflow:
$-5.93M
1W Leistung:
-1.58%
1M Leistung:
+20.92%
6M Leistung:
+5.29%
1J Leistung:
+63.39%
1-Tages-Spanne:
$11.86
$12.45
1-Wochen-Bereich:
$11.67
$12.72
52-Wochen-Spanne:
$6.80
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Firmenname
Mink Therapeutics Inc
Sektor
Branche
Telefon
212-994-8250
Adresse
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
12.14 | 60.48M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
Book value per share of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
MiNK Therapeutics, Inc. Cash Flow – DUS:6Q40 - TradingView
Debt to equity ratio of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mink Therapeutics Inc (INKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mink Therapeutics Inc (INKT) Institutional Confidence - TradingKey
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics (INKT) Q1 2026 earnings summary - Quartr
Mink Therapeutics (INKT) AGM 2026 Summary - Quartr
INKT: Directors and auditor elected, immune restoration strategy advanced, and global trials expanded - TradingView
Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Number of shareholders of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Number of shareholders of MiNK Therapeutics, Inc. – FWB:6Q40 - TradingView
INKT Technical Analysis & Stock Price Forecast - Intellectia AI
MiNK Therapeutics (INKT) Rallies 1.19% as Support Holds Firm Near $11.72IV Contraction - newsline.com
INKT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor SentimentProfit Warning Alert - newsline.com
Discipline and Rules-Based Execution in INKT Response - Stock Traders Daily
Number of shareholders of MiNK Therapeutics, Inc. – LS:A40ZAV - TradingView
INKT Q1 2026 Earnings: EPS Beat on Narrower Loss, But Stock Drops 5%Quarterly Earnings Report - newsline.com
MiNK Therapeutics (INKT) Pulls Back Sharply: Support Test LoomsStrangle Setup - newsline.com
Insider Sell: Barbara Ryan Sells 1,500 Shares of MiNK Therapeuti - GuruFocus
MiNK Therapeutics Q1 earnings call highlights - MSN
Mink Therapeutics director Barbara Ryan sells $19,141 in stock By Investing.com - Investing.com Canada
Mink Therapeutics director Barbara Ryan sells $19,141 in stock - Investing.com India
Director at MiNK Therapeutics (NASDAQ: INKT) sells 1,500 shares - Stock Titan
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting - The Manila Times
How to join MiNK Therapeutics’ June 17 virtual shareholder meeting - Stock Titan
MiNK Therapeutics (INKT) Holds Near $12.0 as Trading Volume Remains ModestIchimoku Kumo Break - newsline.com
MiNK Therapeutics (NASDAQ: INKT) director granted RSU-based stock awards for board service - Stock Titan
MiNK Therapeutics (INKT) director granted stock units instead of cash retainers - Stock Titan
MiNK Therapeutics (INKT) director receives RSUs for board pay - Stock Titan
Director at MiNK Therapeutics (NASDAQ: INKT) receives RSU board compensation - Stock Titan
MiNK Therapeutics (NASDAQ: INKT) director receives RSU grants instead of cash retainers - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
Behavioral Patterns of INKT and Institutional Flows - Stock Traders Daily
INKT Begins Phase 2 Trial for Severe Acute Lung Injury Treatment - GuruFocus
INKT Q1 2026 Earnings: Better-Than-Expected Loss Drives 15.9% Stock RallyEPS Growth Report - thelegaladvocate.com
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - Investing News Network
Mink Therapeutics Doses First Patient in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness - marketscreener.com
Why is Mink Therapeutics stock surging today? By Investing.com - Investing.com Canada
MiNK Therapeutics doses first patient in lung injury trial - Investing.com UK
MiNK Therapeutics doses first patient in lung injury trial By Investing.com - Investing.com Nigeria
New cell therapy tested in Ukraine ICU for severe acute lung injury - Stock Titan
MiNK Therapeutics Q1 2026 Earnings: Narrowed Loss Exceeds Expectations Amid Clinical ProgressEarnings Deceleration Risk - The Legal Advocate
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications - Investing News Network
MiNK Therapeutics Reports Promising Results from Phase 2 Trial of agenT-797 and N-803 Combination Therapy for Coccidioides immitis Infection - Quiver Quantitative
MiNK Therapeutics Reports New Data on agenT-797, an - GlobeNewswire
Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):